Celldex Therapeutics, Inc.
CLDX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $1,351 | $1,205 | $1,677 |
| - Cash | $36 | $23 | $17 | $28 |
| + Debt | $1 | $3 | $3 | $4 |
| Enterprise Value | – | $1,331 | $1,191 | $1,652 |
| Revenue | $0 | $1 | $1 | $1 |
| % Growth | -100% | 5% | -40.9% | – |
| Gross Profit | $0 | $1 | $1 | $0 |
| % Margin | – | 100% | 100% | 30.3% |
| EBITDA | -$66 | -$63 | -$62 | -$55 |
| % Margin | – | -8,627.9% | -8,902.4% | -4,698.6% |
| Net Income | -$67 | -$57 | -$54 | -$47 |
| % Margin | – | -7,753.4% | -7,740.4% | -4,007.8% |
| EPS Diluted | -1.01 | -0.85 | -0.81 | -0.71 |
| % Growth | -18.8% | -4.9% | -14.1% | – |
| Operating Cash Flow | -$49 | -$44 | -$54 | -$32 |
| Capital Expenditures | -$0 | -$1 | -$0 | -$1 |
| Free Cash Flow | -$49 | -$45 | -$55 | -$33 |